Wednesday, 30 November 2016

Pfizer's Herceptin biosimilar succeeds in key breast cancer study

(Reuters) - Pfizer Inc said on Wednesday its experimental biosimilar of Roche Holding AG's blockbuster breast cancer treatment Herceptin met the main goal in a key study.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)